Stockscreener 앱 받기
59.27
1.72%
1.00
전일 마감가:
$58.27
열려 있는:
$59.125
하루 거래량:
3.49M
Relative Volume:
2.02
시가총액:
$11.37B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
22.03
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+0.70%
1개월 성능:
+0.77%
6개월 성능:
-6.54%
1년 성능:
-23.00%
1일 변동 폭
$57.82
$59.73
1주일 범위
$57.59
$62.30
52주 변동 폭
$52.93
$94.85
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.27 | 11.29B | 2.95B | 523.88M | 620.18M | 2.69 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin stock rises on strategic INZY acquisition By Investing.com - Investing.com Nigeria
Hardy sees fertile ground in D.C. for Biomarin’s rare disease strategy - BioCentury
BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech
Healthcare Stocks Lifted By Legal Wins And Drug Approvals - Finimize
Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily
BioMarin stock rises following Inozyme Pharma acquisition - Investing.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc.INZY - The Malaysian Reserve
TD Cowen maintains BioMarin stock Buy rating, $120 target - Investing.com
Top Midday Gainers - marketscreener.com
Cooley, Goodwin Build BioMarin's $270M Inozyme Buy - Law360
BioMarin (BMRN) Set to Acquire Inozyme Pharma for $270M | BMRN Stock News - GuruFocus
BioMarin stock holds $105 target, acquires INZY for $270M By Investing.com - Investing.com India
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
BioMarin stock holds $105 target, acquires INZY for $270M - Investing.com
BioMarin to buy rare disease drugmaker Inozyme for $270M - BioPharma Dive
BioMarin Pharmaceutical Inc. agreed to acquire Inozyme Pharma, Inc.. - marketscreener.com
Transcript : BioMarin Pharmaceutical Inc.M&A Call - marketscreener.com
BioMarin stock rises on strategic INZY acquisition - Investing.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Inozyme Pharma, Inc. (INZY) - TradingView
Inozyme Pharma’s Big Leap: Why INZY Is Surging on BioMarin’s Acquisition News - RagingBull
BioMarin to Acquire Inozyme Pharma for $270M - Contract Pharma
BioMarin Acquires Inozyme Pharma for $270 Million - TipRanks
Inozyme Pharma Merges with BioMarin for $270 Million - TipRanks
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
BioMarin (BMRN) Reiterates 2025 Financial Outlook and Margin Goa - GuruFocus
BioMarin Pharmaceutical (BMRN) Set to Acquire Inozyme Pharma for - GuruFocus
BioMarin (BMRN) Expands Enzyme Therapies with Strategic Acquisition | BMRN Stock News - GuruFocus
BioMarin stock in focus on M&A deal with Inozyme (BMRN:NASDAQ) - Seeking Alpha
BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million - marketscreener.com
BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash - Nasdaq
Biomarin To Acquire Inozyme Pharma - marketscreener.com
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma - Morningstar
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress - Yahoo Finance
Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England - insights.citeline.com
BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
BioMarin's Voxzogo Reduces Tibial Bowing in Young Children With Achondroplasia - marketscreener.com
BioMarin presents new data for Voxzogo - The Pharma Letter
BioMarin (BMRN) Highlights Positive VOXZOGO Data in Achondroplas - GuruFocus
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - Eastern Progress
Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
10 Stocks That Will Make You Rich In 3 Years - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years - Insider Monkey
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BlackRock, Inc. Reduces Stake in BioMarin Pharmaceutical Inc. - GuruFocus
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):